Abstract: The present invention concerns new cationic quaternary ammonium compounds which exhibit excellent adsorption properties on negatively charged surfaces. These ones can notably be obtained firstly by reacting an internal ketone with a twin-tail amine under reductive amination conditions to obtain a twin tail triamine, then subjecting the twin tail triamine to a quaternization reaction. They can also obtained be obtained by the quaternization reaction of a certain diamine.
Abstract: The instant invention provides compounds of formula I which are STING inhibitors, and as such are useful for the treatment of STING-mediated diseases such as inflammation, asthma, COPD and cancer.
Type:
Grant
Filed:
March 15, 2019
Date of Patent:
April 26, 2022
Assignee:
Merck Sharp & Dohme Corp.
Inventors:
Michael D. Altman, Matthew L. Childers, James P. Jewell, Charles A. Lesburg, Tony Siu
Abstract: The present disclosure provides for a synthetic strategy to incorporate a C12?-hydroxy group from the methylene (—CH2-) in a steroid backbone, combining synthetic chemistry and enzymology techniques to develop a selective inhibitor for cytochrome P450 8B1, and developing a selective P450 8B1 inhibitor, which can be used as a tool to study P450 8B1 and treat health issues.
Type:
Grant
Filed:
September 19, 2019
Date of Patent:
January 4, 2022
Assignee:
Board of Regents, the University of Texas System
Abstract: The present invention provides a compound having the structure: for use in combination with an anti-tuberculosis drug for treating a subject infected with M. tuberculosis.
Type:
Grant
Filed:
April 28, 2017
Date of Patent:
July 27, 2021
Assignee:
THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK
Abstract: The invention described herein pertains to substituted indenoisoquinoline compounds as described herein, wherein RA, RD, W, X and Y are defined herein, pharmaceutical compositions and formulations comprising the indenoisoquinoline compounds, their synthesis, and methods for their use in the treatment and/or prevention of cancer.
Abstract: An organic compound and a photoelectric conversion device containing the organic compound are disclosed. The organic compound and device realize high photoelectric conversion efficiency, low dark current and high-speed responsivity. It has been found that when this organic compound and an n-type semiconductor are used in combination, high-speed responsivity can be realized while maintaining high heat resistance, an aspect of which has not been seen when the connection part between a donor part and an acceptor part is a phenylene group.
Abstract: The invention described herein pertains to the synthesis and use of certain N-substituted indenoisoquinoline compounds which inhibit the activity Tyrosyl-DNA Phosphodiesterase I (Tdp1) or Topoisomerase I (Top1) or both, or otherwise demonstrate anticancer activity. Also disclosed are novel N-substituted indenoisoquinoline compounds and pharmaceutical compositions comprising the novel N-substituted indenoisoquinoline compounds.
Type:
Application
Filed:
November 10, 2014
Publication date:
May 14, 2015
Inventors:
Mark S. CUSHMAN, Trung X. Nguyen, Martin M. Conda-Sheridan, Yves George Pommier
Abstract: The invention relates to kinase inhibitors of the formula (I) in which —R1 to R4?H; ether or polyether, amino; NO2; NH-carbamate; NH—CO—R, with R such as defined above; N3 and derivatives thereof of the 1,2,3-triazole type; —R5=—OH; halogen; —OR with R such as defined above; OH-carbamate; OH-carbonate; NH2, NH-carbamate; NH—CO—R, with R such as defined above; N3 and derivatives thereof of the 1,2,3-triazole type; N(R9,R10); —R5??H or a C1-C12 alkyl, —R6?H; R; (R or R?)3—Si, with R such as defined above; optionally substituted aryl, heteroaryl; halogen (iodine); alkynyl; —R7 and R8?H, C1-C12 alkyl; —R9 and R10?H, R (or R?) such as defined above. These compounds can be used as kinase inhibitors in particular for treating cancer.
Type:
Grant
Filed:
January 19, 2009
Date of Patent:
April 7, 2015
Assignee:
Centre National de la Recherche Scientifique
Inventors:
Philippe Olivier Belmont, Laurent Meijer, Philip Cohen, Amaury Patin, Johann Bosson, Peter Gregory Goekjian
Abstract: An object of the present invention is to provide a photoelectric conversion element having a photoelectric conversion film which exhibits heat resistance, a high photoelectric conversion efficiency, a low level of dark currents, rapid response, and sensitivity characteristics to red and can be produced by a vapor deposition processing that is continuously performed under a high-temperature condition. The photoelectric conversion element of the present invention is a photoelectric conversion element in which a conductive film, a photoelectric conversion film containing a photoelectric conversion material, and a transparent conductive film are laminated on one another in this order, wherein the photoelectric conversion material includes a compound represented by Formula (1).
Abstract: The invention described herein pertains to the synthesis and use of certain N-substituted indenoisoquinoline compounds which inhibit the activity Tyrosyl-DNA Phosphodiesterase I (Tdp1) or Topoisomerase I (Top1) or both, or otherwise demonstrate anticancer activity. Also disclosed are novel N-substituted indenoisoquinoline compounds and pharmaceutical compositions comprising the novel N-substituted indenoisoquinoline compounds.
Type:
Grant
Filed:
March 15, 2013
Date of Patent:
December 16, 2014
Assignee:
Purdue Research Foundation
Inventors:
Mark S. Cushman, Trung X. Nguyen, Martin M. Conda-Sheridan, Yves G. Pommier
Abstract: N-Substituted indenoisoquinoline compounds, and pharmaceutical formulations of N-substituted indenoisoquinoline compounds are described. Also described are processes for preparing N-substituted indenoisoquinoline compounds. Also described are methods for treating cancer in mammals using the described N-substituted indenoisoquinoline compounds or pharmaceutical formulations thereof.
Type:
Application
Filed:
July 24, 2014
Publication date:
November 13, 2014
Applicants:
PURDUE RESEARCH FOUNDATION, THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETSR
Inventors:
Mark S. CUSHMAN, Andrew E. MORRELL, Muthukaman NAGARAJAN, Yves G. POMMIER, Keli K. AGAMA, Smitha ANTONY
Abstract: The present invention relates to a droplet microreactor, i.e. a microreactor consisting of a droplet of a specific liquid, the microreactor being wall-less, wherein the interface of the specific liquid with the ambient environment and with the support on which the droplet is deposited defines the limits of the microreactor. The microreactor is characterized in that it consists of a droplet comprising at least one ionic liquid. The present invention also relates to methods for carrying out chemical or biochemical reactions and/or mixes using said droplet microreactor, and also to a lab-on-chip comprising a microreactor according to the invention.
Type:
Application
Filed:
May 6, 2014
Publication date:
October 30, 2014
Inventors:
Gilles MARCHAND, Françoise VINET, Guillaume DE LAPIERRE, Fatima HASSINE, Saïd GMOUH, Michel VAULTIER
Abstract: The invention concerns the production of quinoline compounds containing sulfonic acid groups, the said quinoline compounds and their conversion into dyes containing sulfonic acid groups. The dyes according to the invention are used especially to label analytes, for example to label biomolecules.
Abstract: A 6H-indeno[2,1-b]quinoline derivative has a structure of formula (I). Each of Ar1 and Ar2 is a member selected from the group consisting of a substituted or non-substituted aryl group and a substituted or non-substituted heteroaryl group and R1 to R9 are substituents. The 6H-indeno[2,1-b]quinoline derivative of the present invention is provided with thermal stability. Chemical compounds of the present invention are adequate for the materials of the light-emitting layer of an OLED device with high device performance.
Abstract: N-Substituted indenoisoquinoline compounds, and pharmaceutical formulations of N-substituted indenoisoquinoline compounds are described. Also described are processes for preparing N-substituted indenoisoquinoline compounds. Also described are methods for treating cancer in mammals using the described N-substituted indenoisoquinoline compounds or pharmaceutical formulations thereof.
Type:
Grant
Filed:
October 11, 2011
Date of Patent:
September 9, 2014
Assignees:
Purdue Research Foundation, The United States of America as represented by the Department of Health and Human Services
Inventors:
Mark S. Cushman, Andrew E. Morrell, Muthukaman Nagarajan, Yves G. Pommier, Keli K. Agama, Smitha Antony
Abstract: The invention relates to a process for obtaining compounds derived from tetrahydro-?-carboline, specifically tadalafil and intermediate products from the synthesis, comprising the reaction between piperonal and an alkyl ester of D-tryptophan as a salt, and in the absence of any other component, followed by haloacetylation and a final cyclization with methylamine.
Type:
Grant
Filed:
February 10, 2012
Date of Patent:
September 9, 2014
Assignee:
Interquim, S.A.
Inventors:
Xavier Berzosa Rodríguez, Francisco Marquillas Olondriz
Abstract: [Problem] To provide a compound useful as medicine having PDE4B inhibitory activity, in particular, as an active ingredient of a composition for treating or preventing schizophrenia, Alzheimer's disease, dementia, depression and the like. [Measures for Solution] The present inventors examined compounds having PDE4B inhibitory activity and found that a tricyclic or tetracyclic imidazo[1,2-a]pyridine derivative or salts thereof had a superior PDE4B inhibitory activity, thereby completing the present invention. The imidazo[1,2-a]pyridine derivative can be used as an agent for treating or preventing schizophrenia, Alzheimer's disease, dementia, depression and the like.
Abstract: The present invention provides compounds of formula I: formula (I) wherein X1-X4 and R1-R12 have any of the values defined in the specification, as well as salts and prodrugs thereof, which inhibit major molecular mechanisms associated with bacterial cell division and proliferation so as to be useful for the treatment and/or prevention of bacterial infections. The invention also provides compositions comprising these compounds as well as methods for using these compounds to inhibit bacterial cell division and proliferation and to treat bacterial infections.
Type:
Grant
Filed:
January 15, 2010
Date of Patent:
June 3, 2014
Assignee:
Rutgers, The State University of New Jersey
Inventors:
Edmond J. LaVoie, Ajit Parhi, Daniel S. Pilch, Malvika Kaul
Abstract: The present teachings generally relate to fluorescent dyes, linkable forms of fluorescent dyes, energy transfer dyes, reagents labeled with fluorescent dyes and uses thereof.
Type:
Grant
Filed:
June 21, 2011
Date of Patent:
May 20, 2014
Assignee:
Applied Biosystems, LLC
Inventors:
Ronald Graham, Ruiming Zou, Krishna G. Upadhya, Scott C. Benson
Abstract: The invention described herein pertains to substituted azaindenoisoquinoline compounds, in particular 7-, 8-, 9-, and 10-azaindenoisoquinoline compounds, which are inhibitors of topoisomerase I, processes and intermediates for their syntheses, pharmaceutical compositions of the compounds, and methods of using them in the treatment of cancer.
Type:
Grant
Filed:
July 13, 2012
Date of Patent:
April 1, 2014
Assignee:
Purdue Research Foundation
Inventors:
Mark S. Cushman, Evgeny A. Kiselev, Andrew E. Morrell
Abstract: Indenoisoquinolinone derivatives (I), the manufacturing method and the medical use thereof, which belong to pharmaceutical chemistry and organic chemistry field, are disclosed. These compounds can be used for treating several medical symptoms related to postmenopausal syndrome, uterine fibers deterioration and aortic smooth muscle cells proliferation, especially ER-(+) depend breast cancer. Meanwhile, these compounds can also be used for treating glioma and lung cancer, and have inhibiting effect on tumor metastasis effect on tumor metastasis.
Type:
Grant
Filed:
December 16, 2009
Date of Patent:
March 4, 2014
Assignees:
China Pharmaceutical University, Nanjing Medical University Affiliated Brain Hospital
Inventors:
Hua Xiang, Tianlin Wang, Hong Xiao, Qidong You, Yao Yao, Xiaobo Li, Qingjiang Liao
Abstract: Novel MCH-1 receptor antagonists are disclosed. These compounds are used in the treatment of various disorders, including obesity, anxiety, depression, non-alcoholic fatty liver disease, and psychiatric disorders. Methods of making these compounds are also described in the present invention.
Type:
Grant
Filed:
July 1, 2010
Date of Patent:
January 14, 2014
Assignee:
Albany Molecular Research, Inc.
Inventors:
Peter R. Guzzo, Matthew David Surman, Alan John Henderson, Mark Hadden, Emily Elizabeth Freeman
Abstract: Disclosed are novel gamma secretase inhibitors of the formula (I): or a pharmaceutically acceptable salt, solvate, or ester thereof, wherein L1, n, X, Ar, Y, Z, Q, and Q1 are as defined herein. Also disclosed are methods for inhibiting gamma secretase, methods for treating Alzheimer's disease, methods of treating one or more neurodegenerative diseases, and methods of inhibiting the deposition of amyloid protein (e.g., amyloid beta protein) in, on or around neurological tissue (e.g., the brain) using the compounds of formula 1.0.
Type:
Grant
Filed:
July 15, 2008
Date of Patent:
December 31, 2013
Assignee:
Merck Sharp & Dohme Corp.
Inventors:
Thavalakulamgara K. Sasikumar, Duane A. Burnett, Theodros Asberom, Wen-Lian Wu, Hongmei Li, Ruo Xu, Hubert B. Josien
Abstract: The invention described herein pertains to the synthesis and use of certain N-substituted indenoisoquinoline compounds which inhibit the activity Tyrosyl-DNA Phosphodiesterase I (Tdp1) or Topoisomerase I (Top1) or both, or otherwise demonstrate anticancer activity. Also disclosed are novel N-substituted indenoisoquinoline compounds and pharmaceutical compositions comprising the novel N-substituted indenoisoquinoline compounds.
Type:
Application
Filed:
March 15, 2013
Publication date:
December 26, 2013
Inventors:
MARK S. CUSHMAN, TRUNG X. NGUYEN, MARTIN M. CONDA-SHERIDAN
Abstract: There is provided a compound represented by a specific formula, which has an absorption maximum at 400 nm or more and less than 720 nm in a UV-visible absorption spectrum, wherein a molar extinction coefficient is 10,000 mol?1·l·cm?1 or more at the absorption maximum wavelength, and a difference between a melting point and a deposition temperature (a melting point?a deposition temperature) is 31° C. or more.
Abstract: The invention provides a compound of formula I:or a salt thereof, wherein R3-R8 and X and Y have any of the values described in the specification, as well as compositions comprising a compound of formula I. The compounds are useful as antibacterial agents.
Type:
Application
Filed:
June 24, 2011
Publication date:
May 2, 2013
Inventors:
Edmond J. Lavoie, Ajit Parhi, Daniel S. Pilch
Abstract: An indenoquinolone compounds of Formula (A) is disclosed, wherein the definition of each group is described in the description. These compounds may specifically inhibit topoisomerase I, and they have good activities against many kinds of human tumor cells, such as lung cancer, colon cancer, breast cancer, liver cancer and the like. They can be used in the manufacture of antitumor drugs. The method for preparing the compound of formula (A), and pharmaceutical compositions containing such compounds and the use in the manufacture of antitumor drugs are also disclosed.
Type:
Application
Filed:
May 17, 2011
Publication date:
April 25, 2013
Applicant:
SECOND MILITARY MEDICAL UNIVERSITY, PLA
Abstract: Indenoisoquinolinone derivatives (I), the manufacturing method and the medical use thereof, which belong to pharmaceutical chemistry and organic chemistry field, are disclosed. These compounds can be used for treating several medical symptoms related to postmenopausal syndrome, uterine fibers deterioration and aortic smooth muscle cells proliferation, especially ER-(+) depend breast cancer. Meanwhile, these compounds can also be used for treating glioma and lung cancer, and have inhibiting effect on tumor metastasis effect on tumor metastasis.
Type:
Application
Filed:
December 16, 2009
Publication date:
April 4, 2013
Applicant:
CHINA PHARMACEUTICAL UNIVERSITY
Inventors:
Hua Xiang, Tianlin Wang, Hong Xiao, Qidong You, Yao Yao, Xiaobo Li, Qingjiang Liao
Abstract: The present invention is a method for identifying agents which modulate microRNA activity. The invention involves contacting a cell harboring a microRNA and a microRNA binding sequence, which is operably linked to a nucleic acid molecule encoding a reporter protein, with a test agent and determining whether the test agent increases or decreases the expression of the reporter protein thereby identifying a microRNA modulator. Antagonists identified by this screening assay are provided, as are methods for using the same to inhibit microRNA activity and prevent or treat disease.
Type:
Application
Filed:
June 20, 2012
Publication date:
January 24, 2013
Inventors:
Qihong Huang, Alexander Deiters, Kiranmai Gumireddy
Abstract: This invention provides a therapeutic agent for hepatitis C comprising, as an active ingredient, a compound having anti-HCV activity useful in treatment of hepatitis C. The therapeutic agent for hepatitis C comprises, as an active ingredient, a compound represented by formula (I) or a pharmaceutically acceptable salt thereof.
Abstract: The present invention relates to a method of reducing the production of glutamate from glutamine by glutaminase C in a cell or tissue. The method involves inhibiting glutaminase C activity in the cell or tissue under conditions effective to reduce production of glutamate from glutamine. Compounds for carrying out this method are also disclosed.
Type:
Application
Filed:
March 25, 2010
Publication date:
August 30, 2012
Applicant:
CORNELL UNIVERSITY
Inventors:
Richard A. Cerione, Jon W. Erickson, Kristin Wilson Cerione, Jianbin Wang
Abstract: The present invention relates to a selective estrogen receptor modulator of formula I or Ia: (I) (Ia); or a pharmaceutical acid addition salt thereof; useful for treating vasomotor symptoms, in particular hot flashes, night sweats and other symptoms that affect women around menopause.
Type:
Grant
Filed:
June 23, 2011
Date of Patent:
July 10, 2012
Assignee:
Eli Lilly and Company
Inventors:
Robert Dean Dally, Jeffrey Alan Dodge, Scott Alan Frank, Ronald Jay Hinklin, Timothy Alan Shepherd, Owen Brendan Wallace
Abstract: The present invention discloses novel pharmaceutically acceptable salts of aporphine compounds and carboxyl-group containing agents. Also, the present invention discloses methods for preparing the pharmaceutically acceptable salts. These pharmaceutically acceptable salts are suitable for use in treating and/or preventing hyperglycemic disease and/or several oxidative stress related diseases.
Type:
Grant
Filed:
June 19, 2009
Date of Patent:
June 19, 2012
Assignee:
Standard Chem. & Pharm. Co., Ltd.
Inventors:
Chin-Tsai Fan, Cheng-Shun Lai, Mei-Jung Lin
Abstract: N-Substituted indenoisoquinoline compounds, and pharmaceutical formulations of N-substituted indenoisoquinoline compounds are described. Also described are processes for preparing N-substituted indenoisoquinoline compounds. Also described are methods for treating cancer in mammals using the described N-substituted indenoisoquinoline compounds or pharmaceutical formulations thereof.
Type:
Application
Filed:
October 11, 2011
Publication date:
April 26, 2012
Inventors:
Mark S. Cushman, Andrew E. Morrell, Muthukaman Nagarajan, Yves G. Pommier, Keli K. Agama, Smitha Antony
Abstract: The invention is directed to berberine compounds and processes for the preparation of berberine compounds through an intramolecular Bischler-Napieralski cyclization.
Type:
Grant
Filed:
September 29, 2009
Date of Patent:
April 24, 2012
Assignee:
Mallinckrodt LLC
Inventors:
Christopher W. Grote, Frank W. Moser, John E. Johnson
Abstract: The present invention relates to Indenoisoquinolinone Analogs, compositions comprising an effective amount of an Indenoisoquinolinone Analog and methods for treating or preventing an inflammatory disease, a reperfusion injury, diabetes mellitus, a diabetic complication, reoxygenation injury resulting from organ transplantation, an ischemic condition, a neurodegenerative disease, renal failure, a vascular disease, a cardiovascular disease, cancer, a complication of prematurity, cardiomyopathy, retinopathy, nephropathy, neuropathy, erectile dysfunction or urinary incontinence, comprising administering to a subject in need thereof an effective amount of an Indenoisoquinolinone Analog.
Type:
Grant
Filed:
February 28, 2008
Date of Patent:
February 21, 2012
Assignee:
Inotek Pharmaceuticals Corporation
Inventors:
Prakash Jagtap, Duy-Phong Pham-Huu, Frederick Cohen, Xiaojing Wang
Abstract: The invention provides compositions comprising formula 1 steroids, e.g., 16?-bromo-3?-hydroxy-5?-androstan-17-one hemihydrate and one or more excipients, including compositions that comprise a liquid formulation comprising less than about 3% v/v water. The compositions are useful to make improved pharmaceutical formulations. The invention also provides methods of intermittent dosing of steroid compounds such as analogs of 16?-bromo-3?-hydroxy-5?-androstan-17-one and compositions useful in such dosing regimens. The invention further provides compositions and methods to inhibit pathogen replication, ameliorate symptoms associated with immune dysregulation and to modulate immune responses in a subject using the compounds. The invention also provides methods to make and use these immunomodulatory compositions and formulations.
Abstract: The present invention relates to new CGRP-antagonists of general formula I wherein U, V, X, Y, R1, R2, R3 and R4 are defined as in the description, the tautomers, the isomers, the diastereomers, the enantiomers, the hydrates, the mixtures thereof and the salts thereof and the hydrates of the salts, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, medicaments containing these compounds, their use and processes for preparing them.
Type:
Grant
Filed:
November 21, 2008
Date of Patent:
February 7, 2012
Assignee:
Boehringer Ingelheim International GmbH
Inventors:
Dirk Gottschling, Georg Dahmann, Henri Doods, Annekatrin Heimann, Stephan Georg Mueller, Klaus Rudolf, Gerhard Georg Schaenzle, Dirk Stenkamp
Abstract: The present invention provides compounds of formula I: formula (I) wherein X1-X4 and R1-R12 have any of the values defined in the specification, as well as salts and prodrugs thereof, which inhibit major molecular mechanisms associated with bacterial cell division and proliferation so as to be useful for the treatment and/or prevention of bacterial infections. The invention also provides compositions comprising these compounds as well as methods for using these compounds to inhibit bacterial cell division and proliferation and to treat bacterial infections.
Type:
Application
Filed:
January 15, 2010
Publication date:
January 26, 2012
Inventors:
Edmond J. LaVoie, Ajit Parhi, Daniel S. Pilch, Malvika Kaul
Abstract: Disclosed is a metal complex compound represented by the following Chemical Formula 1, and an organic light emitting diode device including the same. In Chemical Formula 1, M, R1 to R8, A1 to A6, and y are the same as defined in the detailed description.
Abstract: The present invention is a method for identifying agents which modulate microRNA activity. The invention involves contacting a cell harboring a microRNA and a microRNA binding sequence, which is operably linked to a nucleic acid molecule encoding a reporter protein, with a test agent and determining whether the test agent increases or decreases the expression of the reporter protein thereby identifying a microRNA modulator. Antagonists identified by this screening assay are provided, as are methods for using the same to inhibit microRNA activity and prevent or treat disease.
Type:
Application
Filed:
August 1, 2011
Publication date:
January 12, 2012
Applicant:
The Wistar Institute / North Carolina State University
Inventors:
Qihong Huang, Alexander Deiters, Kiranmai Gumireddy
Abstract: The present invention relates to a selective estrogen receptor modulator of formula I or Ia: (I) (Ia); or a pharmaceutical acid addition salt thereof; useful for treating vasomotor symptoms, in particular hot flashes, night sweats and other symptoms that affect women around menopause.
Type:
Application
Filed:
June 23, 2011
Publication date:
November 17, 2011
Applicant:
ELI LILLY AND COMPANY
Inventors:
Robert Dean Dally, Jeffrey Alan Dodge, Scott Alan Frank, Ronald Jay Hinklin, Timothy Alan Shepherd, Owen Brendan Wallace
Abstract: N-Substituted indenoisoquinoline compounds, and pharmaceutical formulations of N-substituted indenoisoquinoline compounds are described. Also described are processes for preparing N-substituted indenoisoquinoline compounds. Also described are methods for treating cancer in mammals using the described N-substituted indenoisoquinoline compounds or pharmaceutical formulations thereof.
Type:
Grant
Filed:
November 13, 2006
Date of Patent:
November 8, 2011
Assignees:
Purdue Research Foundation, The United States of America as represented by the Department of Health and Human Services
Inventors:
Mark S. Cushman, Andrew E. Morrell, Muthukaman Nagarajan, Yves G. Pommier, Keli K. Agama, Smitha Antony
Abstract: Trans-hexahydrobenzoaphenanthridines of the formula (I) wherein X, Y, R1, R2, R3, R4, R5, R6, and R7 are as defined herein, are disclosed. Pharmaceutical formulations including such compounds, and methods of using such compounds for treating a patient suffering from dopamine-related dysfunction of the central or peripheral nervous system are also disclosed.
Abstract: The present teachings generally relate to fluorescent dyes, linkable forms of fluorescent dyes, energy transfer dyes, reagents labeled with fluorescent dyes and uses thereof.
Type:
Grant
Filed:
August 14, 2007
Date of Patent:
July 26, 2011
Assignee:
Applied Biosystems, LLC
Inventors:
Ronald J. Graham, Ruiming Zou, Krishna G. Upadhya, Scott C. Benson
Abstract: 8-Substituted-2,6-methano-3-benzazocines of general structure I in which A is —CH2OH, —CH2NH2, —NHSO2CH3, Q is O or S and Y is O, S or NOH are useful as analgesics, anti-diarrheal agents, anticonvulsants, antitussives and anti-addiction medications.
Abstract: The current invention is in the field of molecular biology/pharmacology and provides compounds which modulate the effects of GPR30 as well as the classical estrogen receptors alpha and beta (ER? and ER?). These compounds may function as agonists and/or antagonists of one or more of the disclosed estrogen receptors.
Type:
Application
Filed:
December 14, 2010
Publication date:
April 21, 2011
Applicant:
STC. UNM
Inventors:
Eric R. PROSSNITZ, Sergey E. Tkatchenko, Chetana M. Revankar, Larry A. Sklar, Jeffrey B. Arterburn, Daniel F. Cimino, Tudor I. Oprea, Cristian-George Bologa, Bruce S. Edwards, Alexander Kiselyov, Susan M. Young
Abstract: The subject of the present invention is to provide a fluorescent substance excitable under visible light, having higher photostability and a long fluorescence lifetime. Another subject is to provide a fluorescent substance consists of a non-natural amino acid applicable to peptide synthesis systems. Searching fluorescent substances, which are fluorescent amino acids and excitable under visible light, having the lowest possible molecular weight for a high photostability resulted in forming a condensed polycyclic aromatic compound by subjecting a compound having an acridone structure to substitution with an amino acid and further condensation with a benzene ring. Thus, the subject is achieved by the fluorescent substance consisting of amino acid-substituted benzoacridone derivative excitable under visible light.
Type:
Grant
Filed:
June 8, 2006
Date of Patent:
April 19, 2011
Assignee:
National University Corporation Okayama University
Abstract: A compound represented by the following formula (I), and a photoelectric conversion device containing the compound: wherein Z1 is a ring containing two carbon atoms and represents a 5-membered ring, a 6-membered ring or a condensed ring containing at least either a 5-membered ring or a 6-membered ring, each of L1, L2 and L3 independently represents an unsubstituted methine group or a substituted methine group, n represents an integer of 0 or more, each of R1, R2, R3, R4, R5 and R6 independently represents a hydrogen atom or a substituent, R1 and R2, R2 and R3, R4 and R5, or R5 and R6 may be combined with each other to form a ring, and each of R21 and R22 independently represents a substituted aryl group, an unsubstituted aryl group, a substituted heteroaryl group or an unsubstituted heteroaryl group, provided that the case where both R21 and R22 are an unsubstituted phenyl group is excluded.